4DMedical (ASX:4DX) secured a contract with the US Department of Defense to conduct a pilot program using its CT Ventilation-Perfusion technology, ahead of the US Food and Drug Administration's clearance of the technology, according to a Monday filing with the Australian bourse.
The technology, which provides a detailed view of lung ventilation and perfusion without radioactive isotopes, will be used to assess lung function and detect conditions like chronic obstructive pulmonary disease and chronic thromboembolic hypertension in 80 active-duty military personnel, the filing said.
Under the agreement, 4DMedical will provide a fixed number of scan analysis reports, helping with the early detection and management of lung conditions, particularly in service members exposed to hazardous environments during military operations.
Financial terms were not disclosed.
Shares of the company soared past 9% in recent Monday trade.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。